Reuters -- Follicular lymphoma patients receiving Roche (ROG.VX) and Biogen Idec’s (BIIB.O) cancer drug Rituxan lived longer without their disease getting worse in a late stage study, the companies said.
Reuters -- Follicular lymphoma patients receiving Roche (ROG.VX) and Biogen Idec’s (BIIB.O) cancer drug Rituxan lived longer without their disease getting worse in a late stage study, the companies said.
